{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:10:04Z","timestamp":1791425404012,"version":"4.3.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.08.037","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:53:33Z","timestamp":1787921613000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vericiguat for the Treatment of Coronary Vasospasm (ViVA)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1107-2513","authenticated-orcid":false,"given":"Hanae F.","family":"Namba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6116-4466","authenticated-orcid":false,"given":"Elize A.M.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukelien C.","family":"Dimitriu-Leen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Meuwissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton A.C.M.","family":"Heestermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina C.","family":"den Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7984-3021","authenticated-orcid":false,"given":"Marcel A.M.","family":"Beijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1515-9623","authenticated-orcid":false,"given":"Coen K.M.","family":"Boerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimane","family":"Mechroubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2952-4849","authenticated-orcid":false,"given":"Timo","family":"Nijkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-0112","authenticated-orcid":false,"given":"Javier","family":"Escaned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester M.","family":"den Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Appelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Suzanne","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etto C.","family":"Eringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Delewi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-0619","authenticated-orcid":false,"given":"Tim P.","family":"van de Hoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.08.037_bib1","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.08.037_bib2","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1093\/eurheartj\/ehaf580","article-title":"Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial","volume":"46","author":"Boerhout","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.08.037_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012017","article-title":"Presence of coronary endothelial dysfunction, coronary vasospasm, and adenosine-mediated vasodilatory disorders in patients with ischemia and nonobstructive coronary arteries","volume":"15","author":"Feenstra","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.08.037_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2021.02.079","article-title":"Vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease is dominated by vasospasm","volume":"333","author":"Konst","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.CIR.101.11.1319","article-title":"Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1\u03b2","volume":"101","author":"Kandabashi","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.037_bib6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.115.306532","article-title":"RhoA\/Rho-kinase in the cardiovascular system","volume":"118","author":"Shimokawa","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2026.08.037_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pharmthera.2007.06.012","article-title":"Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?","volume":"116","author":"Chirkov","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.08.037_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaccas.2020.11.043","article-title":"Repurposing riociguat for treatment of refractory angina resulting from coronary spasm","volume":"3","author":"Mart\u00ednez Pereyra","year":"2021","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jacc.2026.08.037_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrd2222","article-title":"Peroxynitrite: biochemistry, pathophysiology and development of therapeutics","volume":"6","author":"Szab\u00f3","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacc.2026.08.037_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jacc.2026.08.037_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: a patent review","volume":"31","author":"Sandner","year":"2021","journal-title":"Exp Opin Ther Pat"},{"key":"10.1016\/j.jacc.2026.08.037_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1156456","article-title":"Drug repurposing\u2014a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)","volume":"10","author":"McChord","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.08.037_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.037_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jacc.2026.08.037_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacc.2026.08.037_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacc.2026.08.037_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.08.037_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.08.037_bib19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the soluble guanylate cyclase stimulator in heart failure studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2026.08.037_bib20","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.08.037_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cpt.2574","article-title":"Vericiguat in combination with short-acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study","volume":"111","author":"Boettcher","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2026.08.037_bib22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/cts.13238","article-title":"Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: the randomized, phase Ib, VISOR study","volume":"15","author":"Boettcher","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jacc.2026.08.037_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2026.107451","article-title":"Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study","volume":"299","author":"Namba","year":"2026","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.08.037_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2023.02.043","article-title":"Design and rationale of the NetherLands registry of invasive Coronary vasomotor Function Testing (NL-CFT)","volume":"379","author":"Crooijmans","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib25","first-page":"2565","article-title":"International standardization of diagnostic criteria for vasospastic angina","volume":"38","author":"Beltrame","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.08.037_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcin.2021.10.003","article-title":"Acetylcholine rechallenge: a first step toward tailored treatment in patients with coronary artery spasm","volume":"15","author":"Seitz","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.08.037_bib27","doi-asserted-by":"crossref","first-page":"H1086","DOI":"10.1152\/ajpheart.00335.2024","article-title":"Relationship between peripheral and intracoronary blood flow in patients with angina and non-obstructive coronary arteries","volume":"327","author":"Woudstra","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1117\/1.JBO.24.8.080901","article-title":"Clinical applications of laser speckle contrast imaging: a review","volume":"24","author":"Heeman","year":"2019","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.jacc.2026.08.037_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCIMAGING.111.970418","article-title":"Assessment of skin microvascular function and dysfunction with laser speckle contrast imaging","volume":"5","author":"Mah\u00e9","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.08.037_bib30","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1093\/eurheartj\/ehy529","article-title":"Systemic microvascular dysfunction in microvascular and vasospastic angina","volume":"39","author":"Ford","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.08.037_bib31","first-page":"H1435","article-title":"Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide","volume":"270","author":"Meredith","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib32","first-page":"2167","article-title":"Assessing endothelial vasodilator function with the Endo-PAT 2000","volume":"44","author":"Axtell","year":"2010","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jacc.2026.08.037_bib33","doi-asserted-by":"crossref","first-page":"H32","DOI":"10.1093\/eurheartjsupp\/suac058","article-title":"Remote digital smart device follow-up in prospective clinical trials: early insights from ORBITA-2, ORBITA-COSMIC, and ORBITA-STAR","volume":"24","author":"Ganesananthan","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jacc.2026.08.037_bib34","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165541","article-title":"A novel effective method for the assessment of microvascular function in male patients with coronary artery disease: a pilot study using laser speckle contrast imaging","volume":"49","author":"Borges","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.jacc.2026.08.037_bib35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jdiacomp.2016.12.007","article-title":"Assessment of microvascular endothelial function in type 1 diabetes using laser speckle contrast imaging","volume":"31","author":"Saldanha de Mattos Matheus","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacc.2026.08.037_bib36","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1002\/sim.10133","article-title":"Bayesian transition models for ordinal longitudinal outcomes","volume":"43","author":"Rohde","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2026.08.037_bib37","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","article-title":"Stratified medical therapy using invasive coronary function testing in angina: the CorMicA trial","volume":"72","author":"Ford","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamacardio.2024.5670","article-title":"Safety, feasibility, and diagnostic yield of invasive coronary function testing: Netherlands Registry of Invasive Coronary Vasomotor Function Testing","volume":"10","author":"Crooijmans","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.08.037_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jacc.2026.03.027","article-title":"Randomized, placebo-controlled trial of chronic total occlusion percutaneous coronary intervention in stable angina","volume":"88","author":"Khan","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib41","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(24)00256-3","article-title":"Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial","volume":"403","author":"Foley","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.08.037_bib42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0735-1097(93)90310-W","article-title":"Randomized placebo-controlled trial of amlodipine in vasospastic angina","volume":"21","author":"Chahine","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.08.037_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239039","article-title":"Comparison of nebivolol versus diltiazem in improving coronary artery spasm and quality of life in patients with hypertension and vasospastic angina: a prospective, randomized, double-blind pilot study","volume":"15","author":"Kook","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2026.08.037_bib44","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jcmg.2022.03.012","article-title":"Efficacy of diltiazem to improve coronary vasomotor dysfunction in ANOCA: the EDIT-CMD randomized clinical trial","volume":"15","author":"Jansen","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.08.037_bib45","article-title":"Efficacy and safety of the endothelin-1 receptor antagonist macitentan in epicardial and microvascular vasospasm; a proof-of-concept study","volume":"47","author":"Feenstra","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacc.2026.08.037_bib46","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.124.069901","article-title":"Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial","volume":"150","author":"Morrow","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.08.037_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2026-004115","article-title":"Women\u2019s IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR): a randomised controlled trial","volume":"13","author":"Pepine","year":"2026","journal-title":"Open Heart"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726075911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726075911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:26:57Z","timestamp":1790022417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726075911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0735109726075911"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.08.037","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vericiguat for the Treatment of Coronary Vasospasm (ViVA)","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}